Your JourneY fromInD to nDA... AnD BeYonD

Patients 172,350+ 277,350+ 890,100+ 99,600+ 1,451,100+

Studies 1,500+ 1,400+ 1,250+ 150+ 4,500+

InvestigatorSites 6,300+ 33,900+ 91,750+ 6,600+ 139,200+

Source: Internal metrics 2010-2014

Number

of studies

2010-2014

48 of the 50best selling-drugs in 2013 were

developed in partnership with

Covance Central Laboratory Services.

Unparalleled therapeutic experience over the

past 5 years. Over 4,500 studies, more

than 2x as many as any other central lab.

Unique insights in all therapeutic areas...

...and at every step of the process.

PHASe I

InD nDAPHASe II totAL

PHASe III PHASe IV

CentralNervous System

845

Oncology

1,097

Endocrine/Metabolic

707

ImmuneSystem

849

InfectiousDiseases

503

per day by reducing the risk of delaysto your trial completion milestones

Our on-time delivery can save you

$600,000+

Proven results at every stage of the trial

our SoLutIonS to meet Your StuDY mILeStoneS

StArt uP

eXeCutIon

DeLIVerY

BETTER DECISIONS, FASTEROur global automation strategy delivers consistent results.

SAVING SAMPLES MEANS SAVING MONEY Data reconciliation speeds data submissions.

Covance delivered 97.9% of data packages on time in 2014.

Reportabletest yields

98.2%

Sample receiptwithin stability

99.0%

You can count on our ability to deliver:

Over 1,850,000 samples to and from

95 countries each year.

the Americas + 1.888.CoVAnCe + 1.609.452.4440

europe / Africa + 00.800.2682.2682 Asia Pacific + 800.6568.3000

© Copyright 2015 Covance Inc. INFCLS001-1214

Covance Inc., headquartered in Princeton, NJ, is the drug development business of Laboratory Corporation of America® Holdings (LabCorp®). Covance is the marketing name for Covance Inc. and its subsidiaries around the world.

COVANCE 47% COMPETITOR A B C

INVESTIGATORS PREFER COVANCE BY 2xMeet your enrollment milestones faster with

engaged investigators and on-time kit delivery.

Source: Life

Science Strategy

Group survey, 2013